Homepage Top Section2

The multimillion-pound drug discovery alliance will bring together Cancer Research UK’s network of scientists and drug discovery expertise, LifeArc’s therapeutic antibody engineering and development expertise and Ono’s expertise

Mayzent is claimed to the first oral drug to treat secondary progressive MS with active disease. Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS),

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain

The public-private partnership between Evotec and GARDP will strive to address the increasing threat of antimicrobial resistance (AMR). It will combine GARDP’s clinical expertise and Evotec’s drug discovery

Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the

Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter,

Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with elevated LDL-C. The company has submitted new drug

Upon completion of the transaction, Biogen Hillerød will become the fourth biopharmaceutical contract development and manufacturing site of Fujifilm. The large-scale biologics manufacturing facility is installed with 6